List view / Grid view
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Using atomistic simulations, a team has demonstrated how coronavirus Spike proteins move and vibrate to let the virus through cell walls.
In this article, Janssen Pharmaceuticals’ Global Head of Discovery Neuroscience discusses the findings of their recent study which highlighted new roles for two gene products involved in human deafness which could enable drug discovery for some prevalent auditory disorders.
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Using a new CRISPR-Cas9 tagging strategy, researchers have developed a method that enables the imaging of hundreds of proteins in parallel.
Lan Zhu from Arizona State University explains how cryo-EM methods can be used to obtain structural information on membrane proteins such as GPCRs.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
Researchers have identified that autoreactive B cells and a protein that enables them to invade joints could be promising drug targets for the most common inflammatory arthritis.
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
